Interventions to treat premature ejaculation: a systematic review short report

Katy Cooper,* Marrissa Martyn-St James, Eva Kaltenthaler, Kath Dickinson and Anna Cantrell

School of Health and Related Research (ScHARR) Technology Assessment Group, The University of Sheffield, Sheffield, UK

*Corresponding author

Declared competing interests of authors: none

Published March 2015
DOI: 10.3310/hta19210

Scientific summary

Interventions to treat premature ejaculation
Health Technology Assessment 2015; Vol. 19: No. 21
DOI: 10.3310/hta19210

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Premature ejaculation (PE) is commonly defined as ejaculation with minimal sexual stimulation before, on or shortly after penetration and before the person wishes it. PE can be either lifelong and present since first sexual experiences (primary), or acquired (secondary), beginning later. Prevalence rates internationally are 20–30%. Treatments include behavioural techniques, anaesthetic creams and sprays, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), phosphodiesterase-5 (PDE5) inhibitors, analgesics such as tramadol (Zydol SR®, Grünenthal) and other interventions. Dapoxetine (Priligy®, Menarini) (a SSRI) is the only drug to have received approval for the treatment of PE in the UK.

Objectives

The objective was to systematically review the evidence for the clinical effectiveness of behavioural, topical and systemic treatments for PE in the form of a Health Technology Assessment (HTA) short report.

Data sources

The following electronic databases were searched from inception to 6 August 2013 for published and unpublished research evidence: MEDLINE; EMBASE; Cumulative Index to Nursing and Allied Health Literature; The Cochrane Library including the Cochrane Systematic Reviews Database, Cochrane Controlled Trials Register, Database of Abstracts of Reviews of Effects and the HTA database; ISI Web of Science, including Science Citation Index, and the Conference Proceedings Citation Index-Science. The US Food and Drug Administration website and the European Medicines Agency website were also searched.

Methods

The systematic review included randomised controlled trials (RCTs) evaluating any intervention relevant to the UK in men with primary and/or secondary PE. Comparators included other interventions, waiting list control, placebo, or no treatment. RCTs were identified through literature searching of databases from inception to August 2013 and from existing reviews. Quality assessment was conducted for existing reviews and for further RCTs not captured in a review. For RCTs within existing reviews, data were extracted from the review and not from the original RCT publication. When no RCT evidence was identified for an intervention, other study types were considered. Outcomes included intravaginal ejaculatory latency time (IELT), sexual satisfaction, control over ejaculation, relationship satisfaction, self-esteem, quality of life, treatment acceptability and adverse events (AEs).

Results

A total of 103 studies (102 RCTs) were included (65 from reviews). The majority of RCTs not already in reviews (n = 37) were of unclear methodological quality.
Behavioural interventions

Twelve RCTs were identified. Behavioural therapies improved IELT and sexual satisfaction compared with waiting list control, and behavioural therapies combined with pharmacological therapies were better than either intervention alone in improving IELT, sexual satisfaction, sexual anxiety and ejaculation control. When reported, no AEs were associated with behavioural interventions alone.

Topical anaesthetics

Nine RCTs assessed treatment over 4–12 weeks. Both eutectic mixture of local anaesthetics cream and topical eutectic mixture for PE spray were significantly more effective than placebo in increasing IELT [mean difference (MD) 6.44 minutes, 95% confidence interval (CI) 6.01 to 6.87 minutes] and 3.30 minutes (95% CI 1.33 to 5.27 minutes); both p < 0.00001. AEs include loss of sensation and irritation (men and women) and loss of erection with applications ≥ 20 minutes.

Selective serotonin reuptake inhibitors other than dapoxetine

Forty-two RCTs assessed SSRIs, mostly taken daily, and treatment duration was 4–12 weeks. Citalopram (Cipramil®, Lundbeck) significantly increased IELT compared with placebo or no treatment [MD 0.25 minutes (95% CI −0.06 to 0.56 minutes) to 4.62 minutes (95% CI 4.21 to 5.03 minutes); p < 0.00001] and improved sexual satisfaction. Escitalopram (Cipralex®, Lundbeck) significantly increased IELT compared with placebo (MD 1.2 minutes, 95% CI 0.79 to 1.61 minutes; p < 0.00001). Fluoxetine significantly increased IELT compared with placebo (MD 2.41 minutes, 95% CI 2.10 to 2.73 minutes; p < 0.00001). Fluvoxamine did not significantly increase IELT compared with placebo. Paroxetine significantly increased IELT compared with placebo (MD 5.34 minutes, 95% CI 3.79 to 6.89 minutes; p < 0.00001) and improved sexual satisfaction. Sertraline significantly increased IELT compared with placebo (MD 2.72 minutes, 95% CI 1.77 to 3.67 minutes; p < 0.00001) and improved ejaculation control. AEs included nausea, headache, insomnia, dry mouth, diarrhoea, drowsiness, dizziness, somnolence, decreased libido and anejaculation.

Selective serotonin reuptake inhibitors: dapoxetine

Eight RCT reports assessed licensed doses of dapoxetine, generally taken on demand prior to intercourse. Treatment duration was 2–24 weeks. Dapoxetine 30 mg and 60 mg significantly increased IELT compared with placebo [MD 1.16 minutes (95% CI 0.94 to 1.39 minutes) and 1.66 minutes (95% CI 1.46 to 1.87 minutes); p < 0.00001] and dapoxetine 60 mg was more effective than 30 mg (MD 0.46 minutes, 95% CI 0.19 to 0.74 minutes; p = 0.0009). Similar effects are evident for ejaculatory control, sexual satisfaction, global impression of change and clinical benefit. AEs included nausea, diarrhoea, headache and dizziness and appearing to be dose dependent.

Serotonin–noradrenaline reuptake inhibitors

Three RCTs were identified. One 12-week trial indicated that duloxetine (Cymbalta®, Eli Lilly & Co Ltd) is better than placebo in increasing IELT (MD 1.52 minutes, 95% CI 0.08 to 2.24 minutes; p < 0.00001). Evidence from two RCTs suggests venlafaxine is not effective at increasing IELT compared with placebo. Duloxetine side effects included dry mouth and nausea. Venlafaxine caused significantly more side effects than placebo.

Tricyclic antidepressants

Thirteen RCTs were identified all evaluating clomipramine (oral or nasal). RCT evidence summarised from reviews suggests a significant increase in IELT with clomipramine compared with placebo; however, data were poorly reported. Inhaled clomipramine 4 mg appears effective at increasing IELT when compared with placebo (1.68 minutes, 95% CI 1.06 to 2.29 minutes; p < 0.00001). AEs were not well reported but included dry mouth and constipation. Inhaled clomipramine may cause some local irritation.
**Phosphodiesterase-5 inhibitors**

Twelve RCTs were identified, but IELT was poorly reported. Vardenafil (Levitra®, Bayer) and tadalafil (Cialis®, Eli Lilly & Co Ltd) significantly increased IELT compared with placebo [based on one RCT each; MD 3.80 minutes (95% CI 3.30 to 4.30 minutes) and 2.59 minutes (95% CI 1.28 to 3.90 minutes); \( p = 0.006 \) and \( p < 0.00001 \), respectively], but there was no significant difference in one RCT between sildenafil and placebo. Sexual satisfaction favoured PDE5 inhibitors over placebo. Sildenafil plus sertraline or behavioural therapy was better than sildenafil alone. AEs included flushing, headache and palpitations.

**Alpha-blockers**

Two RCTs were identified, neither assessing IELT. Evidence from one 8-week RCT showed improvements for terazosin (Hytrin®, AMCO) compared with placebo in ejaculation control. The current evidence base for alpha-blockers in the treatment of PE is limited.

**Tramadol**

Seven RCTs were identified. Treatment duration was 6–24 weeks. Tramadol significantly increased IELT compared with placebo (MD 1.35 minutes, 95% CI 0.63 to 2.07 minutes; \( p = 0.0002 \)) and improved sexual satisfaction. Tramadol plus behavioural therapy improved IELT over behavioural therapy alone (MD 1.65 minutes, 95% CI 0.30 to 3.00 minutes; \( p = 0.02 \)). There was no significant difference between tramadol and paroxetine. AEs included erectile dysfunction, constipation, nausea, headache, somnolence, dry mouth, dizziness, pruritus and vomiting. Addiction potential was not assessed.

**Acupuncture**

Two 4-week RCTs were identified. Acupuncture significantly increased IELT compared with sham acupuncture but comparisons with SSRIs were inconsistent. AEs were not well reported.

**Chinese medicine**

Five RCTs were identified. In one 2-week trial, Chinese medicine was more effective than treatment as usual (1.57 minutes, 95% CI 1.11 to 2.03 minutes; \( p < 0.00001 \)). In one 4-week trial, fluoxetine improved IELT compared with Chinese medicine (0.60 minutes, 95% CI 0.19 to 1.01 minutes; \( p < 0.00001 \)). AEs were not well reported.

**Delay devices**

One RCT compared a desensitising band plus stop–start technique compared with behavioural therapy plus stop–start technique (treatment duration unclear). IELT appeared improved with the desensitising band. AEs (soreness with overuse) were minimal when used as directed.

**Yoga**

No RCTs were identified. In one non-RCT comparing yoga with fluoxetine over 12 weeks, both yoga and fluoxetine significantly improved IELT from baseline, but fluoxetine significantly increased IELT compared with yoga. A high proportion of partners reported a good sexual satisfaction with yoga. AEs were not reported.

**Discussion**

**Strengths**

This report systematically reviews the evidence for PE treatments relevant to the UK. In contrast to many existing reviews, this review meta-analysed data across RCTs where appropriate, used appropriate outcome measures (MD) to summarise IELT, avoided double-counting of participants and considered pairwise and crossover RCT data separately. An assessment of methodological quality is also included.
Limitations and uncertainties
Owing to the large volume of evidence, data for RCTs reported in reviews were extracted from the review article and not the original RCT publication. Thus, the reliability of these data cannot be guaranteed. Similarly, the methodological quality of individual RCTs reported in existing reviews was not assessed by this assessment report.

Generalisability of findings
Most trials involved men with primary PE without a concomitant condition such as erectile dysfunction, mainly recruited from specialist sexual health settings. The effectiveness of treatments for men with secondary PE, PE concomitant to another condition, or not attending specialised clinics, is less certain. Included trials were undertaken in various European Union (EU) and non-EU countries. Variability in trial populations, PE definitions and IELT entry criteria, cultural attitudes towards PE and acceptability of treatments also limits generalisability of findings. Treatment duration among trials ranged from 2 to 24 weeks. The long-term effectiveness and safety for patients either continuing or withdrawing from treatment are unknown. Furthermore, patient adherence to and acceptability of treatments have not been fully evaluated. The improvements in IELT ranged from 1 to 6 minutes. While these effects were statistically significant, it is difficult to quantify how acceptable and meaningful these changes are for men with PE without being able to evaluate the relationship between IELT, ejaculation control, and sexual satisfaction. There is currently no consensus on what constitutes a clinically significant threshold response to interventions for PE.

Conclusions
Implications for service provision
Several interventions provided statistically significant improvements of between 1 and 6 minutes in time to ejaculation (IELT), including pharmacological interventions (SSRIs and other antidepressants, PDE5 inhibitors, tramadol), topical anaesthetics and behavioural therapies. Many interventions also demonstrated improvements in sexual satisfaction and other outcomes. Behavioural therapy combined with pharmacotherapy was better than behavioural therapy or pharmacotherapy alone. Pharmacological and topical therapies are associated with some AEs. Trial duration was a maximum of 12 weeks for most interventions (24 weeks for dapoxetine and tramadol). Different interventions have different modes of action and individual patients may have a preference for pharmacological or behavioural interventions, so maintaining a range of options (to be used individually or in combination) may remain a useful approach in the treatment of PE.

Suggested research priorities
Assessment of long-term safety and effectiveness of interventions (> 6 months) is required and should assess whether or not initial treatment effects are maintained long term, whether or not the effects end with treatment cessation, whether or not treatments require dose escalation to maintain initial treatment effects and whether or not treatments can be stopped and resumed, as well as AEs associated with long-term treatment. This could be addressed by reviewing the literature for these treatments in other conditions, supplemented by longer-term studies in PE, possibly observational studies or longer-term follow-up of RCT participants.

The current evidence base does not include sufficient direct comparisons to inform a judgement regarding the ‘best treatment’ in terms of either efficacy or safety as active treatments are compared with placebo/no treatment by the majority of RCTs. Future research could consider head-to-head trials or a mixed treatment comparison/network meta-analysis, as well as assessment of cost-effectiveness of the different interventions. As dapoxetine has been specifically developed for PE and has been extensively evaluation for this indication, head-to-head comparisons between this and other treatments might be informative. The effect of treatments used sequentially or in combination should also be further assessed. For behavioural therapies, further research is required to determine the components, intensity and delivery
of interventions that are most effective. However, patients may have preferences for different types of treatment (e.g. pharmacological or behavioural) and, therefore, maintaining a range of options may be a useful approach.

Future research should also consider an evaluation of clinically meaningful increases in IELT, including evaluation of the relationship between increases in IELT, ejaculatory control and sexual satisfaction, and whether or not increases of a few minutes in IELT are more meaningful to some patients than others. The trade-off between an improvement in IELT and other effectiveness outcomes compared with AEs and inconvenience should also be further evaluated.

**Funding**

Funding for this study was provided by the HTA programme of the National Institute for Health Research.
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 5.116

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is assessed for inclusion in the Database of Abstracts of Reviews of Effects.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org).  

Editorial contact: nihredit@southampton.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 13/12/01. The contractual start date was in July 2013. The draft report began editorial review in December 2013 and was accepted for publication in April 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2015. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of *Health Technology Assessment* and NIHR Journals Library

**Professor Tom Walley**  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

**NIHR Journals Library Editors**

**Professor Ken Stein**  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andree Le May**  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key**  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck**  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

**Professor Aileen Clarke**  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Peter Davidson**  Director of NETSCC, HTA, UK

**Ms Tara Lamont**  Scientific Advisor, NETSCC, UK

**Professor Elaine McColl**  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

**Professor John Powell**  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Institute of Child Health, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:** nihredit@southampton.ac.uk